Martha Allen Zeiger

Title: Martha Allen Zeiger: Innovator in Thyroid Cancer Diagnostics

Introduction

Martha Allen Zeiger is a prominent inventor based in Bethesda, MD (US). She has made significant contributions to the field of medical diagnostics, particularly in the area of thyroid cancer. With a total of 4 patents, her work has advanced the understanding and diagnosis of thyroid tumors.

Latest Patents

One of her latest patents is titled "Alternative splice variant patterns of human telomerase reverse transcriptase (hTERT) in thyroid tumors to distinguish benign from malignant." This invention relates to a method for determining if a thyroid tumor in a subject is malignant. It involves assessing the amount of TERT mRNA that lacks the β sequence and the amount that comprises the β sequence. A preponderance of TERT mRNA with the β sequence indicates malignancy, while a preponderance lacking the β sequence suggests a benign tumor. Another significant patent is a "Diagnostic tool for diagnosing benign versus malignant thyroid lesions." This invention utilizes genes that are differentially expressed in benign and malignant thyroid lesions for the diagnosis and staging of thyroid cancer.

Career Highlights

Martha has worked with esteemed institutions such as Johns Hopkins University and the United States Department of Health and Human Services. Her research has been pivotal in enhancing diagnostic techniques for thyroid cancer, thereby improving patient outcomes.

Collaborations

Throughout her career, Martha has collaborated with notable professionals, including Christopher Umbricht and Steven K Libutti. These collaborations have further enriched her research and innovations in the field.

Conclusion

Martha Allen Zeiger's contributions to thyroid cancer diagnostics exemplify her dedication to medical innovation. Her patents reflect a commitment to improving diagnostic methods, ultimately benefiting patients and the medical community.